EGFR and glioblastoma: The phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/Mtor) pathway is frequently activated in GBM due to PTEN loss or EGFR mutations, promoting cell proliferation, survival, and resistance to apoptosis [29].